Regression of left ventricular hypertrophy and control of hypertension in the spontaneously hypertensive rat (SHR): Oxprenolol versus hydrochlorothiazide

H. Idikio, P. G. Fernandez, Christopher Triggle, B. K. Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The control of hypertension with antihypertensive agents, in the spontaneously hypertensive rats (SHR) can result in regression of established cardiac hypertrophy. This study compared the effects of therapy with oxprenolol (Ox) and with hydrochlorothiazide (Htz) for (1) regression of established left ventricular hypertrophy (LVH) and (2) blood pressure control. Three groups of SHR and 3 comparable groups of Wistar-Kyoto (WKY) rats, matched for age, sex and body wt, were treated with tap water (Gp I), 60-200 mg hydrochlorothiazide kg-1 day-1 (Gp II) and 15-500 mg oxprenolol kg-1 day-1 (Gp III) for 13 weeks. Systolic and diastolic blood pressures (SBP, DBP mmHg), left ventricular wt/body wt ratio (LVwt/Bwt mg g-1) and left ventricular wall thickness (LVWT mm) were recorded. Oxprenolol lowered both systolic (mean ± S.E. mmHg, 130 ± 7 vs 189 ± 8; P<0.01) and diastolic blood pressures (mean ± S.E. mmHg, 104 ± 6 vs 159 ± 6; P<0.001) and caused regression of left ventricular hypertrophy (mean ± S.E. mg g-1, 2.91 ± 0.06 vs 3.10 ± 0.09; P<0.05). In contrast, hydrochlorothiazide did not control blood pressure (mean ± S.E. mmHg, 183 ± 5 vs 189 ± 6 and 152 ± 5 vs 156 ± 6), but it did cause regression of left ventricular hypertrophy (mean ± S.E. mg g-1, 2.67 ± 0.03 vs 3.10 ± 0.09; P<0.01). Left ventricular wall thickness, measured in the mid-ventricular region, was significantly reduced only by hydrochlorothiazide (mean ± S.E. mm, 2.76 ± 0.06 vs 3.21 ± 0.01; P<0.05). These results suggest that regression of left ventricular hypertrophy can occur with or without control of hypertension in the SHR.

Original languageEnglish
Pages (from-to)43-48
Number of pages6
JournalClinical and Investigative Medicine
Volume6
Issue number1
Publication statusPublished - 1983
Externally publishedYes

Fingerprint

Oxprenolol
Hydrochlorothiazide
Left Ventricular Hypertrophy
Inbred SHR Rats
Blood Pressure
Hypertension
Inbred WKY Rats
Cardiomegaly
Antihypertensive Agents
Water

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{90bea9894d5a412e93245e1d8eb0a53f,
title = "Regression of left ventricular hypertrophy and control of hypertension in the spontaneously hypertensive rat (SHR): Oxprenolol versus hydrochlorothiazide",
abstract = "The control of hypertension with antihypertensive agents, in the spontaneously hypertensive rats (SHR) can result in regression of established cardiac hypertrophy. This study compared the effects of therapy with oxprenolol (Ox) and with hydrochlorothiazide (Htz) for (1) regression of established left ventricular hypertrophy (LVH) and (2) blood pressure control. Three groups of SHR and 3 comparable groups of Wistar-Kyoto (WKY) rats, matched for age, sex and body wt, were treated with tap water (Gp I), 60-200 mg hydrochlorothiazide kg-1 day-1 (Gp II) and 15-500 mg oxprenolol kg-1 day-1 (Gp III) for 13 weeks. Systolic and diastolic blood pressures (SBP, DBP mmHg), left ventricular wt/body wt ratio (LVwt/Bwt mg g-1) and left ventricular wall thickness (LVWT mm) were recorded. Oxprenolol lowered both systolic (mean ± S.E. mmHg, 130 ± 7 vs 189 ± 8; P<0.01) and diastolic blood pressures (mean ± S.E. mmHg, 104 ± 6 vs 159 ± 6; P<0.001) and caused regression of left ventricular hypertrophy (mean ± S.E. mg g-1, 2.91 ± 0.06 vs 3.10 ± 0.09; P<0.05). In contrast, hydrochlorothiazide did not control blood pressure (mean ± S.E. mmHg, 183 ± 5 vs 189 ± 6 and 152 ± 5 vs 156 ± 6), but it did cause regression of left ventricular hypertrophy (mean ± S.E. mg g-1, 2.67 ± 0.03 vs 3.10 ± 0.09; P<0.01). Left ventricular wall thickness, measured in the mid-ventricular region, was significantly reduced only by hydrochlorothiazide (mean ± S.E. mm, 2.76 ± 0.06 vs 3.21 ± 0.01; P<0.05). These results suggest that regression of left ventricular hypertrophy can occur with or without control of hypertension in the SHR.",
author = "H. Idikio and Fernandez, {P. G.} and Christopher Triggle and Kim, {B. K.}",
year = "1983",
language = "English",
volume = "6",
pages = "43--48",
journal = "Clinical and Investigative Medicine",
issn = "0147-958X",
publisher = "The Canadian Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Regression of left ventricular hypertrophy and control of hypertension in the spontaneously hypertensive rat (SHR)

T2 - Oxprenolol versus hydrochlorothiazide

AU - Idikio, H.

AU - Fernandez, P. G.

AU - Triggle, Christopher

AU - Kim, B. K.

PY - 1983

Y1 - 1983

N2 - The control of hypertension with antihypertensive agents, in the spontaneously hypertensive rats (SHR) can result in regression of established cardiac hypertrophy. This study compared the effects of therapy with oxprenolol (Ox) and with hydrochlorothiazide (Htz) for (1) regression of established left ventricular hypertrophy (LVH) and (2) blood pressure control. Three groups of SHR and 3 comparable groups of Wistar-Kyoto (WKY) rats, matched for age, sex and body wt, were treated with tap water (Gp I), 60-200 mg hydrochlorothiazide kg-1 day-1 (Gp II) and 15-500 mg oxprenolol kg-1 day-1 (Gp III) for 13 weeks. Systolic and diastolic blood pressures (SBP, DBP mmHg), left ventricular wt/body wt ratio (LVwt/Bwt mg g-1) and left ventricular wall thickness (LVWT mm) were recorded. Oxprenolol lowered both systolic (mean ± S.E. mmHg, 130 ± 7 vs 189 ± 8; P<0.01) and diastolic blood pressures (mean ± S.E. mmHg, 104 ± 6 vs 159 ± 6; P<0.001) and caused regression of left ventricular hypertrophy (mean ± S.E. mg g-1, 2.91 ± 0.06 vs 3.10 ± 0.09; P<0.05). In contrast, hydrochlorothiazide did not control blood pressure (mean ± S.E. mmHg, 183 ± 5 vs 189 ± 6 and 152 ± 5 vs 156 ± 6), but it did cause regression of left ventricular hypertrophy (mean ± S.E. mg g-1, 2.67 ± 0.03 vs 3.10 ± 0.09; P<0.01). Left ventricular wall thickness, measured in the mid-ventricular region, was significantly reduced only by hydrochlorothiazide (mean ± S.E. mm, 2.76 ± 0.06 vs 3.21 ± 0.01; P<0.05). These results suggest that regression of left ventricular hypertrophy can occur with or without control of hypertension in the SHR.

AB - The control of hypertension with antihypertensive agents, in the spontaneously hypertensive rats (SHR) can result in regression of established cardiac hypertrophy. This study compared the effects of therapy with oxprenolol (Ox) and with hydrochlorothiazide (Htz) for (1) regression of established left ventricular hypertrophy (LVH) and (2) blood pressure control. Three groups of SHR and 3 comparable groups of Wistar-Kyoto (WKY) rats, matched for age, sex and body wt, were treated with tap water (Gp I), 60-200 mg hydrochlorothiazide kg-1 day-1 (Gp II) and 15-500 mg oxprenolol kg-1 day-1 (Gp III) for 13 weeks. Systolic and diastolic blood pressures (SBP, DBP mmHg), left ventricular wt/body wt ratio (LVwt/Bwt mg g-1) and left ventricular wall thickness (LVWT mm) were recorded. Oxprenolol lowered both systolic (mean ± S.E. mmHg, 130 ± 7 vs 189 ± 8; P<0.01) and diastolic blood pressures (mean ± S.E. mmHg, 104 ± 6 vs 159 ± 6; P<0.001) and caused regression of left ventricular hypertrophy (mean ± S.E. mg g-1, 2.91 ± 0.06 vs 3.10 ± 0.09; P<0.05). In contrast, hydrochlorothiazide did not control blood pressure (mean ± S.E. mmHg, 183 ± 5 vs 189 ± 6 and 152 ± 5 vs 156 ± 6), but it did cause regression of left ventricular hypertrophy (mean ± S.E. mg g-1, 2.67 ± 0.03 vs 3.10 ± 0.09; P<0.01). Left ventricular wall thickness, measured in the mid-ventricular region, was significantly reduced only by hydrochlorothiazide (mean ± S.E. mm, 2.76 ± 0.06 vs 3.21 ± 0.01; P<0.05). These results suggest that regression of left ventricular hypertrophy can occur with or without control of hypertension in the SHR.

UR - http://www.scopus.com/inward/record.url?scp=0020692938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020692938&partnerID=8YFLogxK

M3 - Article

C2 - 6219850

AN - SCOPUS:0020692938

VL - 6

SP - 43

EP - 48

JO - Clinical and Investigative Medicine

JF - Clinical and Investigative Medicine

SN - 0147-958X

IS - 1

ER -